Shanghai Haohai Biological Technology Full Year 2023 Earnings: EPS: CN¥2.44 (vs CN¥1.04 in FY 2022)

Shanghai Haohai Biological Technology (HKG:6826) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥2.65b (up 26% from FY 2022).
• Net income: CN¥416.1m (up 131% from FY 2022).
• Profit margin: 16% (up from 8.6% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: CN¥2.44 (up from CN¥1.04 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai Haohai Biological Technology Earnings Insights

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 30% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 5.1% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Shanghai Haohai Biological Technology's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.